(S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN drug) (NNS combinations))) (, ,) (VP (VBD termed) (S (NP (NN polypharmacy)))) (, ,)) (VP (VBZ is) (ADJP (JJ common)) (S (VP (TO to) (VP (VB treat) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ complex) (NNS diseases)) (CC and) (NP (JJ co-existing) (NNS conditions))))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP (NP (DT a) (JJ major) (NN consequence)) (PP (IN of) (NP (NN polypharmacy)))) (VP (VBZ is) (NP (NP (DT a) (ADJP (RB much) (JJR higher)) (NN risk)) (PP (IN of) (NP (JJ adverse) (NN side) (NNS effects))) (PP (IN for) (NP (DT the) (NN patient))))) (. .))
(S (NP (NNP Polypharmacy) (JJ side) (NNS effects)) (VP (VBP emerge) (PP (IN because) (IN of) (NP (NP (JJ drug-drug) (NNS interactions)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (NN activity)) (PP (IN of) (NP (CD one) (NN drug)))) (VP (MD may) (VP (VB change) (SBAR (IN if) (S (VP (VBN taken) (PP (IN with) (NP (DT another) (NN drug))))))))))))) (. .))
(S (NP (NP (DT The) (NN knowledge)) (PP (IN of) (NP (NN drug) (NNS interactions)))) (VP (VBZ is) (VP (ADJP (JJ limited)) (SBAR (IN because) (S (NP (DT these) (JJ complex) (NNS relationships)) (VP (VP (VBP are) (ADJP (JJ rare))) (, ,) (CC and) (VP (VBP are) (ADVP (RB usually)) (RB not) (VP (VBN observed) (PP (IN in) (NP (ADJP (RB relatively) (JJ small)) (JJ clinical) (NN testing)))))))))) (. .))
(S (S (VP (VBG Discovering) (NP (JJ polypharmacy) (JJ side) (NNS effects)))) (ADVP (RB thus)) (VP (VBZ remains) (NP (NP (DT an) (JJ important) (NN challenge)) (PP (IN with) (NP (NP (JJ significant) (NNS implications)) (PP (IN for) (NP (JJ patient) (NN mortality))))))) (. .))
(S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP present) (NP (NP (NNP Decagon)) (, ,) (NP (NP (DT an) (NN approach)) (PP (IN for) (S (VP (VBG modeling) (NP (JJ polypharmacy) (NN side) (NNS effects)))))))) (. .))
(S (NP (DT The) (NN approach)) (VP (VBZ constructs) (NP (NP (DT a) (JJ multimodal) (NN graph)) (PP (IN of) (NP (NP (JJ protein-protein) (NNS interactions)) (, ,) (NP (JJ drug-protein) (NN target) (NNS interactions)) (, ,) (CC and) (NP (NP (DT the) (NN polypharmacy) (NN side) (NNS effects)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN represented) (PP (IN as) (NP (NP (JJ drug-drug) (NNS interactions)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (DT each) (NN side) (NN effect)) (VP (VBZ is) (NP (NP (DT an) (NN edge)) (PP (IN of) (NP (DT a) (JJ different) (NN type)))))))))))))))))) (. .))
(S (NP (NNP Decagon)) (VP (VBZ is) (VP (VBN developed) (ADVP (RB specifically)) (S (VP (TO to) (VP (VB handle) (NP (NP (JJ such) (NNS multimodal) (VBP graphs)) (PP (IN with) (NP (NP (DT a) (JJ large) (NN number)) (PP (IN of) (NP (NN edge) (NNS types))))))))))) (. .))
(S (NP (PRP$ Our) (NN approach)) (VP (VBZ develops) (NP (NP (DT a) (JJ new) (NN graph) (JJ convolutional) (JJ neural) (NN network)) (PP (IN for) (NP (NP (JJ multirelational) (NN link) (NN prediction)) (PP (IN in) (NP (JJ multimodal) (NNS networks))))))) (. .))
(S (NP (NNP Decagon)) (VP (VBZ predicts) (NP (NP (DT the) (JJ exact) (NN side) (NN effect)) (PRN (, ,) (SBAR (IN if) (FRAG (NP (DT any)))) (, ,)) (SBAR (WHPP (IN through) (WHNP (WDT which))) (S (NP (DT a) (VBN given) (NN drug) (NN combination)) (VP (NNS manifests) (ADVP (RB clinically))))))) (. .))
(S (NP (NNP Decagon)) (VP (ADVP (RB accurately)) (VBZ predicts) (NP (JJ polypharmacy) (NN side) (NNS effects)) (, ,) (S (VP (VBG outperforming) (NP (NNS baselines)) (PP (IN by) (NP (QP (IN up) (TO to) (CD 69)) (NN %)))))) (. .))
(S (NP (PRP We)) (VP (VBP find) (SBAR (IN that) (S (NP (PRP it)) (ADVP (RB automatically)) (VP (VBZ learns) (NP (NP (NNS representations)) (PP (IN of) (NP (NP (NN side) (NNS effects)) (ADJP (JJ indicative) (PP (IN of) (NP (NP (NN co-occurrence)) (PP (IN of) (NP (NN polypharmacy))) (PP (IN in) (NP (NNS patients))))))))))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP (NNP Decagon)) (VP (NNS models) (ADVP (RB particularly) (RB well)) (NP (NP (JJ side) (NNS effects)) (PP (IN with) (NP (DT a) (JJ strong) (JJ molecular) (NN basis)))) (, ,) (SBAR (IN while) (S (PP (IN on) (NP (ADJP (RB predominantly) (JJ non-molecular)) (NN side) (NNS effects))) (, ,) (NP (PRP it)) (VP (VBZ achieves) (NP (JJ good) (NN performance)) (PP (IN because) (IN of) (NP (NP (JJ effective) (NN sharing)) (PP (IN of) (NP (NN model) (NNS parameters))) (PP (IN across) (NP (NN edge) (NNS types))))))))) (. .))
(S (NP (NNP Decagon)) (VP (VBZ creates) (NP (NNS opportunities) (S (VP (TO to) (VP (VB use) (NP (JJ large) (UCP (NNS pharmacogenomic) (CC and) (JJ patient)) (NNS data)) (S (VP (TO to) (VP (VB flag) (CC and) (VB prioritize) (NP (NN side) (NNS effects)) (PP (IN for) (NP (JJ follow-up) (NN analysis))))))))))) (. .))
